Our experience in the use of a Russian preparation of pulmonary surfactant in the treatment of acute respiratory distress syndrome and severe pneumonia in children

Six critical patients aged 2 months to 13 years with lung diseases were treated by pulmonary surfactant preparation. Three of these children developed the acute respiratory distress syndrome in the presence of grave pneumonia (1 case), asphyxial drowing (1 case), and small-small intestinal invaginat...

Full description

Saved in:

Bibliographic Details
Published in:	Anesteziologiia i reanimatologiia no. 2; p. 61
Main Authors:	Tsybul'kin, E K, Rozenberg, O A, Seĭliev, A A, Volchkov, V A, Zaĭtseva, N V, Kuz'menko, I G, Loshakova, L V, Pelogievskaia, Z I, Portniagin, I V, Shefer, S P
Format:	Journal Article
Language:	Russian
Published:	Russia (Federation) 01-03-1999
Subjects:	Acute Disease Adolescent Child Child, Preschool Diagnosis, Differential Humans Infant Infant, Newborn Pneumonia - diagnosis Pneumonia - drug therapy Pneumonia - therapy Pulmonary Surfactants - administration & dosage Pulmonary Surfactants - therapeutic use Radiography, Thoracic Respiration, Artificial Respiratory Distress Syndrome, Newborn - diagnosis Respiratory Distress Syndrome, Newborn - drug therapy Respiratory Distress Syndrome, Newborn - therapy Time Factors
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Six critical patients aged 2 months to 13 years with lung diseases were treated by pulmonary surfactant preparation. Three of these children developed the acute respiratory distress syndrome in the presence of grave pneumonia (1 case), asphyxial drowing (1 case), and small-small intestinal invagination (1 case), three others developed acute bilateral large focal pneumonia with or without repeated atelectases. The drug Surfactant-BL was administered in a dose of 400 micrograms/m2 by instillations (2 cases) or by inhalation aerosols. The drug improved blood gases, lung compliance, x-ray picture, and clinical status of all patients, permitting a decrease in IMV/SIMV parameters within 12-48 h after the last administration and discontinuation of IMV/SIMV in 3 patients within 24 h after 1 or two administrations. Five children survived, 1 (with asphyxial drowning) died with brain edema and wedging syndrome. Surfactant-BL is a safe and effective drug; administration through alveolar nebulisers should be preferred.
ISSN:	0201-7563